Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
Completed · Phase 3 · Has a placebo group
Conditions studied: Osteoporosis, Postmenopausal
In brief
The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. * Effects of arzoxifene on the uterus. * The safety of arzoxifene and any side effects.
Key facts
- Study ID
- NCT00088010
- Run by
- Eli Lilly and Company
- People needed
- 9369
- Starts
- 2004-06-01
- Expected to finish
- 2009-11-01
- Last updated by the study team
- 2010-06-02
Who can join
Age: 60 and older, up to 85. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- 60-85 years of age
- Female
- At least two years since last menstrual cycle
You may not qualify if…
- Abnormal or unexplained vaginal bleeding.
- Bone disorders, other than osteoporosis or low bone mass
- History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer).
- History of cerebral vascular accidents or venous thromboembolic events
- Medications outlined
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Elk Grove, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.